MEDICAL POLICY No. 91571-R8

OSTEOARTHRITIS OF THE KNEE

Effective Date: September 1, 2024

Review Dates: 2/10, 2/11, 2/12, 2/13, 2/14, 2/15, 2/16, 2/17, 2/18, 2/19, 2/20, 5/20, 8/20, 8/21, 8/22, 8/23, 11/23, 5/24 Status: Current

Date Of Origin: February 10, 2010

Summary of Changes

- Change: Clarified procedures/services prior authorized according to TurningPoint criteria.
- Deletion: Removed references to retired policies

I. POLICY/CRITERIA

- A. The following procedures are medically necessary according to TurningPoint criteria:
 - 1. Autologous chondrocyte implantation (e.g., Carticel) for the repair of articular cartilage.
 - 2. Autologous cellular implant derived from adipose tissue, autologous adipose derived regenerative cell therapy, or autologous microfragmented adipose injection (e.g., Lipogems).
 - 3. Bone marrow aspirate concentrate (BMAC) and platelet rich plasma (PRP) injections.
 - 4. MAKOplasty® knee resurfacing. The MAKO® device may also be used for computer assisted navigation; as with other similar devices, this is not separately payable.
 - 5. Mesenchymal stem cell injections.
- B. The following treatments for osteoarthritis of the knee are considered experimental, investigational, or unproven:
 - 1. Coolief Cooled Radiofrequency Ablation for the treatment of hip and/or knee pain associated with osteoarthritis of the knee.
 - 2. Genicular articular embolization

II. MEDICAL NECESSITY REVIEW

Prior authorization for certain drug, services, and procedures may or may not be required. In cases where prior authorization is required, providers will submit a request demonstrating that a drug, service, or procedure is medically necessary. For more information, please refer to the <u>Priority Health Provider Manual</u>.



III. APPLICATION TO PRODUCTS

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

- **HMO/EPO:** *This policy applies to insured HMO/EPO plans.*
- **POS:** This policy applies to insured POS plans.
- PPO: This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.
- ASO: For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.
- INDIVIDUAL: For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.
- MEDICARE: Coverage is determined by the Centers for Medicare and Medicaid Services (CMS) and/or the Evidence of Coverage (EOC); if a coverage determination has not been adopted by CMS, this policy applies.
- MEDICAID/HEALTHY MICHIGAN PLAN: For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule located at: <u>http://www.michigan.gov/mdch/0,1607,7-132-2945_42542_42543_42546_42551-159815--,00.html</u>. If there is a discrepancy between this policy and the Michigan Medicaid Provider Manual located at: <u>http://www.michigan.gov/mdch/0,1607,7-132-2945_5100-87572--,00.html</u>, the Michigan Medicaid Provider Manual will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.

IV. DESCRIPTION

Cellular-based therapies have been proposed as a treatment option for patients with osteoarthritis (OA) of the knee who are refractory to conventional medical therapies and are ineligible for joint replacement. Biologic injections, which include mesenchymal stem cells, have been marketed for the treatment of OA. Mesenchymal stem cells (MSCs) are self-renewing and multipotent cells capable of differentiating into multiple cell types. They were originally isolated from the bone marrow stroma but have recently been identified in other tissues. Bone marrow aspirate is considered to be the most accessible source and the most common place to isolate MSCs for treatment of musculoskeletal disease. Bone marrow aspirate concentrate (BMAC) can be extracted and derived from different bones in the body. For orthopedic indications, bone marrow is generally extracted from the iliac crest, though other sites may be utilized. BMAC is under investigation as an alternative to autologous bone grafting from the iliac crest, Centrifugation of bone marrow aspirate (e.g., Harvest SmartPrep centrifuge) to concentrate MSCs is being utilized to increase the concentration of osteoprogenitor cells. Some research has suggested that stem cell concentration may relate to overall effectiveness, hence the use of centrifugation to create

MEDICAL POLICY No. 91571-R8 Osteoarthritis of the Knee

BMAC. In addition to bone marrow, MSC can also be harvested from adipose tissue. Autologous cellular implant derived from adipose tissue, also known as autologous adipose derived regenerative cell therapy, or autologous microfragmented adipose injection (e.g., Lipogems) has been purposed for the treatment of degenerative joint disease or osteoarthritis. The system involves a minimally invasive procedure to harvest fat-derived stem cells then concentrate or microfragment, and finally transfer the tissue back to the patient after knee arthroscopy. Biologic injections are unproven or unsafe for current use in orthopedic conditions.

MAKOplasty (Stryker) is a robotic-assisted and computer-navigated procedure for the partial resurfacing of the knee (PKR). PKR involves the surgical removal and replacement of only the damaged surface of the knee joint with the intent of minimizing trauma to surrounding healthy bone and tissue. In a pilot study, Lonner et al (2010) compared the post-operative radiographical alignment of the tibial component with the preoperatively planned position in 31 knees in 31 consecutive patients undergoing unicompartmental knee arthroplasty (UKA) using robotic arm-assisted bone preparation and in 27 consecutive patients who underwent unilateral UKA using conventional manual instrumentation. There is insufficient published evidence to assess the safety and/or impact on health outcomes or patient management of Makoplasty for osteoarthritis of the knee.

Cooled radiofrequency ablation is a minimally invasive procedure that uses focused energy delivered through water-cooled electrodes to destroy tissue. The Coolief Cooled Probe and Radiofrequency Kit are indicated for creating radiofrequency lesions nervous tissue for the relief of pain, and lesions of the genicular nerves for the management of moderate-to-severe knee pain of more than 6 months with conservative therapy, including medication, in patients with radiologically confirmed osteoarthritis (grade 2-4) and a positive response (\geq 50% reduction in pain) to a diagnostic genicular nerve block.

Genicular or geniculate artery embolization (GAE) is a minimally invasive treatment which aims to treat OA of the knee by reducing synovial arterial hypervascularity. The procedure involves advancing a femoral catheter into the knee using x-ray imaging guidance, and an embolic agent is injected into the catheter to block the blood flow in the genicular arteries and capillaries supplying the synovium. Reducing arterial flow to the synovium reduces inflammation and nerve growth, thereby decreasing pain and possibly OA disease progression (Padia, 2021). GAE is an outpatient interventional radiology procedure performed with the patient under moderate sedation. A consensus panel from the Society of Interventional Radiologists states that while the limited published data available suggest that GAE is effective in reducing knee pain from OA, additional safety and efficacy data to confirm their role in the algorithm for management of OA (Ahmed, 2021). In a systemic review of GAE, the authors concluded that mild-tomoderate OA treated by GAE using different embolic particles could generally be considered safe. The procedure resulted in significant and sustained pain

MEDICAL POLICY No. 91571-R8

improvement as well as better functional status in the studies reviewed. However, because of the paucity of high-quality trials (available studies lacked a control group), further investigation is needed to examine GAE's long-term outcomes, its comparative efficacy with other treatment modalities, and its role in the therapeutic approach (Torkin, 2021).

V. CODING INFORMATION

CPT/HCPCS:

Codes Not Covered for the indications in the policy:

- 0232T Injection(s), platelet rich plasma, any tissue, including image guidance, harvesting and preparation when performed
- 0481T Injection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed
- 0565T Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation
- 0566T Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral
- 20999 Unlisted procedure, musculoskeletal system, general
- 27599 Unlisted procedure, femur or knee
- 37242 Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (eg, congenital or acquired arterial malformations, arteriovenous malformations, arteriovenous fistulas, aneurysms, pseudoaneurysms)
- 38206 Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
- 38232 Bone marrow harvesting for transplantation; autologous
- 38241 Hematopoietic progenitor cell (HPC); autologous transplantation
- 64454 Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches,
 - including imaging guidance, when performed (Not covered if billed for Coolief for any product)
- 64624 Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed (*Not covered if billed for Coolief for any product*)
- C9809 Cryoablation needle (e.g., iovera system), including needle/tip and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023) (Covered for Medicare and Medicaid)



VI. REFERENCES

- 1. Ackroyd CE, Chir B. Development and early results of a new patellofemoral arthroplasty. Clin Orthop Relat Res. 2005;(436):7-13.
- 2. Ackroyd CE, Newman JH, Evans R, et al. The Avon patellofemoral arthroplasty: five-year survivorship and functional results. J Bone Joint Surg Br. 2007; 89(3):310-315.
- Ahmed O, Block J, Mautner K, Plancher K, Anitescu M, Isaacson A, Filippiadis DK, Epelboym Y, Bercu Z, Mitchell JW, Cristescu M, White SB, Prologo JD. Percutaneous Management of Osteoarthritis in the Knee: Proceedings from the Society of Interventional Radiology Research Consensus Panel. J Vasc Interv Radiol. 2021; 32(6):919.e1-919.e6. doi: 10.1016/j.jvir.2021.03.409. Epub 2021 Mar 6. PMID: 33689834.
- 4. American Academy of Orthopaedic Surgeons (AAOS). Treatment of osteoarthritis of the knee (non-arthroplasty). Rosemont (IL): American Academy of Orthopaedic Surgeons; 2008. Available at: http://www.aaos.org/Research/guidelines/OAKguideline.pdf.
- American Academy of Orthopaedic Surgeons. Appropriate Use Criteria for Non-Arthroplasty Treatment of Osteoarthritis of the Knee. December 6, 2013. Available @ https://www.aaos.org/globalassets/quality-and-practiceresources/osteoarthritis-of-the-knee/auc-non-arthroplasty-treatmentosteoarthritis-knee.pdf (Retrieved July 5, 2023).
- 6. Argenson JN, Flecher X, Parratte S, Aubaniac JM. Patellofemoral arthroplasty: an update. Clin Orthop Relat Res. 2005; 440:50-53.
- 7. Butler JE, Shannon R. Patellofemoral arthroplasty with a custom-fit femoral prosthesis. Orthopedics. 2009; 32(2):81-85.
- 8. Coughling RP et al. Adipose-Derived Stem Cell Transplant Technique for Degenerative Joint Disease. Arthrosc Tech. 2017 Oct; 6(5).
- 9. Credentialing Resource Center (CRC). Orthopedic surgery. Clin Privil White Pap. 2008;(149):1-12.
- 10. Delanois RE, McGrath MS, Ulrich SD, et al. Results of total knee replacement for isolated patellofemoral arthritis: when not to perform a patellofemoral arthroplasty. Orthop Clin N Am. 2008; 39:381-388.
- Food and Drug Administration. 510 (K) Premarket Notification.K163236. Coolief Cooled Radiofrequency Kit. Available at <u>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K163</u> 236 (Accessed August 28, 2024).
- 12. Food and Drug Administration. 510(k) Premarket Notification. K163461. Coolief Cooled RF Probe. Available at <u>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K163</u> <u>461</u> (Accessed August 28, 2024).
- Food and Drug Administration. 510(k) Premarket Notification. The Lipogems System. K161636.

https://www.accessdata.fda.gov/cdrh_docs/pdf16/K161636.pdf (Accessed August 28, 2024)

- 14. Hayes, Inc. Autologous Microfragmented Adipose Tissue Injection for Treatment of Osteoarthritis. Health Technology Assessment, March 11, 2020.
- 15. Hayes, Inc. Bone Marrow Aspirate Concentrate and Platelet-Rich Plasma for Orthopedic Use, June 2014.
- 16. Hayes, Inc. Bone Marrow Aspirate Concentration Systems, May 11, 2017
- 17. Hayes, Inc. Coolef Cooled RF (Avanos Medical Inc.) for Knee and Hip Pain. Evidence Analysis Research Brief, November 11, 2019.
- 18. Hayes, Inc. MAKOplasty (MAKO Surgical Corporation) for Knee Arthroplasty, February 4, 2016.
- 19. Hayes, Inc. Patellofemoral Replace for Osteoarthritis. October 13, 2009
- 20. Hayes, Inc. Patellofemoral Replacement for Isolated Osteoarthritis of the Knee. November 16, 2017
- 21. Hayes, Inc. Platelet-Rich Plasma for Knee Osteoarthritis: A Review of Reviews. November 9, 2017.
- 22. Hendrix MR, Ackroyd CE, Lonner JH. Revision patellofemoral arthroplasty: three- to seven-year follow-up. J Arthroplasty. 2008; 23(7):977-983.
- 23. Hunter C et al. Cooled Radiofrequency Ablation Treatment of the Genicular Nerves in the Treatment of Osteoarthritic Knee Pain: 18- and 24-Month Results. Pain Pract. 2020 Mar; 20(3): 238–246.
- Jevsevar DS. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg. 2013 Sep;21(9):571-6. doi: 10.5435/JAAOS-21-09-571. PMID: 23996988.
- 25. Kim Y-H, Yoon S-H, Park J-W. Does robotic-assisted TKA result in better outcome scores or long-term survivorship than conventional TKA? A randomized, controlled trial. Clin Orthop Relat Res. 2020;478(2):266-275.
- 26. Leadbetter WB, Kolisek FR, Levitt RL, et al. Patellofemoral arthroplasty: a multi-centre study with minimum 2-year follow-up. Int Orthop. 2008 Dec 5.
- 27. Leadbetter WB, Ragland PS, Mont MA. The appropriate use of patellofemoral arthroplasty: An analysis of reported indications, contraindications, and failures. Clin Orthop Relat Res. 2005; 436:91-99.
- Lonner JH. Patellofemoral arthroplasty. J Am Acad Orthop Surg. 2007; 15(8):495-506.
- 29. Lonner JH. Patellofemoral arthroplasty: the impact of design on outcomes. Orthop Clin North Am. 2008; 39(3):347-354.
- 30. Merchant AC. A modular prosthesis for patellofemoral arthroplasty: design and initial results. Clin Orthop Relat Res. 2005 ;(436):40-46.
- 31. Nicol SG, Loveridge JM, Weale AE, et al. Arthritis progression after patellofemoral joint replacement. Knee. 2006; 13(4):290-295.
- Padia SA, Genshaft S, Blumstein G, Plotnik A, Kim GHJ, Gilbert SJ, Lauko K, Stavrakis AI. Genicular Artery Embolization for the Treatment of Symptomatic Knee Osteoarthritis. JB JS Open Access. 2021;6(4):e21.00085. doi: 10.2106/JBJS.OA.21.00085. PMID: 34703964; PMCID: PMC8542160.
- Panchal J, Malanga G, and Skeinkop M. Safety and Efficacy of Percutaneous Injection of Lipogems Micro-Fractured Adipose Tissue for Osteoarthritic Knees. Am J Orthop. 2018 Nov;47(11).

Page 6 of 8

- 34. Paxton EW, Fithian DC. Outcome instruments for patellofemoral arthroplasty. Clin Orthop Relat Res. 2005 ;(436):66-70.
- 35. Reddy RD et al. Cooled Radiofrequency Ablation of Genicular Nerves for Knee Osteoarthritis Pain: A Protocol for Patient Selection and Case Series. Anesth Pain Med. 2016 Dec; 6(6): e396976.
- 36. Russo A et al. Autologous Micro-Fragmented Adipose Tissue for the Treatment of Diffuse Degenerative Knee Osteoarthritis: An Update at 3 Year Follow-Up. J Exp Orthop. 2018 Dec 19;5(1):52.
- 37. Russo A, Condello V, Madonna V, et al. Autologous and micro-fragmented adipose tissue for the treatment of diffuse degenerative knee osteoarthritis. J Exp Orthop. 2017 Oct 3;4(1):33
- Schiavone Panni A, Vasso M, Braile A, et al. Preliminary results of autologous adipose-derived stem cells in early knee osteoarthritis: identification of a subpopulation with greater response. Int Orthop. 2019 Jan; 43(1):7-13.
- 39. Sisto DJ, Sarin VK. Patellofemoral arthroplasty with a customized trochlear prosthesis. Orthop Clin North Am. 2008; 39(3):355-362, vi-vii.
- 40. Sisto DJ, Sarin VK. Custom patellofemoral arthroplasty of the knee. J Bone Joint Surg Am. 2006; 88(7):1475-1480.
- 41. Torkian P, Golzarian J, Chalian M, et al. Osteoarthritis-related knee pain treated with genicular artery embolization: A systematic review and metaanalysis. Orthop J Sports Med. 2021;9(7).
- 42. van Wagenberg JM, Speigner B, Gosens T, de Waal Malefijt J. Midterm clinical results of the Autocentric II patellofemoral prosthesis. Int Orthop. 2009 Feb 18.
- 43. Van Jonbergen HPW, Werkman DM, van Kampen A. Conversion of patellofemoral arthroplasty to total knee arthroplasty: A matched case-control study of 13 patients. Acta Orthop. 2009; 80(1):62-66.



AMA CPT Copyright Statement:

All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion.

Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.

Page 8 of 8